Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Gastric Cancer Clinical Trial

Official title:

A Multi-Center Phase I Trial of Neratinib and Fam-trastuzumab Deruxtecan in Advanced Refractory Gastric and Esophageal Cancer Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05274048
• Other study ID #: 21-1069
• Secondary ID: GI-200
• Status: Recruiting
• Phase: Phase 1
• Start date: June 24, 2022
• Est. completion date: June 2027

Study information

• Verified date: March 2024
• Source: Fox Chase Cancer Center
• Contact: Namrata Vijavergia, MD
• Phone: 215-214-1676
• Email: Namrata.Vijayvergia[@]fccc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is Phase 1 dose finding trial with potential dose expansion to evaluate the safety, toxicity, recommended phase 2 dose (RP2D), and maximum tolerated dose (MTD) of Neratinib plus TDxD using a standard 3+3 dose escalation design in Patients with metastatic or unresectable gastric adenocarcinoma (including GEJ tumors) that are HER2-overexpressing (IHC 3+ or IHC2+/ISH+). Patients must have progressed or been intolerant of at least one prior line of chemotherapy + HER2 directed therapy.

Description:

This is Phase 1 dose finding trial with potential dose expansion to evaluate the safety, toxicity, recommended phase 2 dose (RP2D), and maximum tolerated dose (MTD) of Neratinib plus TDxD using a standard 3+3 dose escalation design in Patients with metastatic or unresectable gastric adenocarcinoma (including GEJ tumors) that are HER2-overexpressing (IHC 3+ or IHC2+/ISH+). Patients must have progressed or been intolerant of at least one prior line of chemotherapy + HER2 directed therapy. A total of 18 patients will be enrolled. It is anticipated that the trials may escalate through 3 different dose levels of Neratinib (120 mg, 160 mg, 200 mg). Both drugs have GI toxicity specifically diarrhea and the combination may have risk of increased toxicity from TDxD due to increase cellular uptake of the cytotoxic payload. If the initial dose level 0 is deemed too toxic, the study investigators and DSMB can make a decision to allow dose reduction of TDxD to 4.4mg/kg (dose level -1) and reintroduction of neratinib at dose level 0, if the toxicities are felt to be related to TDxD. For cycle 1, patients will start with Neratinib lead in starting at Day -7 and TDxD will be administered on Day 1. Each future treatment cycle will comprise of Neratinib administered PO daily for a 21-day cycle with food. TDxD will be administered intravenously on day 1 of a 21-day cycle. All patients will undergo screening transthoracic echocardiography or multigated acquisition scan (MUGA) prior to initiating treatment and every 9 weeks while on treatment. Tumor assessment must be performed every 3 cycles (+/-7 days). The assessment will be conducted before day 1 of each cycle as possible.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 18
• Est. completion date: June 2027
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients must have been diagnosed with histologically or cytologically confirmed gastric adenocarcinoma (including adenocarcinomas of the gastroesophageal junction), and been deemed unresectable or have at least one site of metastatic disease

2. Patients must have evaluable or measurable disease by RECIST 1.1 criteria

3. Patients' tumors must have HER2-overexpressing (IHC 3+ or IHC2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma.

4. Patients must have received at least one prior line of HER2 directed therapy for metastatic/unresectable disease and completed treatment at least 2 weeks prior to C1D1

5. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

6. Age > 18 years.

7. ECOG performance status 0-2

8. Patients must have normal organ and marrow function as defined below

• Leukocytes > 3,000/mcL

• Absolute neutrophil count > 1,500/mcL

• Platelets > 90,000/mcL

• Hemoglobin > 9 gm/dl

• Total bilirubin < 2 times institutional normal limits

• AST/ALT (SGOT/SGPT) < 5 times institutional normal limits if liver metastases and </+ 2 times institutional normal limits otherwise

• Creatinine < 2.0mg/dL OR

• Creatinine clearance > 50 Ml/min/1.73 m2 for patients with creatinine levels above institutional normal

9. Left Ventricular Ejection Fraction = 45% or lower limit of normal.

10. Chemotherapy is harmful to the human fetus. For this reason, females of childbearing potential must be willing to use an effective method of contraception, as outlined in Section 4.4, for the course of the study through at least 6 months after the last dose of study medication. Males who have women of childbearing (WOCB) partners must agree to use an effective method of contraception as outlined in Section 4.4 for the course of the study through 8 months after the last dose of study medication.

11. Patients should be willing and able to swallow oral tablet medications

12. Ability to understand and willingness to sign a written informed consent and HIPAA consent document

Exclusion Criteria:

1. Patients who have had chemotherapy, or radiotherapy within 2 weeks prior to C1D1 or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier (secondary hypothyroidism from prior immunotherapy is permissible if controlled on thyroid hormone replacement). Recovery is defined as any treatment onset adverse events returning to baseline or otherwise deemed not clinically significant.

2. Patients may not be receiving any other investigational agents for advanced cancer and must not have received prior treatment with TDxD

3. Immunotherapy and treatments involving any investigational agents must be discontinued for >21 days before Cycle 1 Day 1 (C1D1)

4. Patients with known untreated brain metastases are excluded from this study because of their poor prognosis and frequent development of neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Treated brain metastases are allowed (requires stability on MRI at least 4 weeks after initial treatment). Patients with treated brain metastases are allowed to be treated with steroid and/or anti-convulsants if the dose remains stable or decreases over the last 4 weeks prior to C1D1

5. Patients with ongoing diarrhea (> 4 bowel movements/day) unresolved despite medical and best supportive care in the two weeks preceding therapy

6. Patients will be excluded if they have had interstitial lung disease or pneumonitis or were suspected to have interstitial lung disease or pneumonitis that could not be ruled out on imaging at screening or if they had a history of noninfectious interstitial lung disease or pneumonitis that had been treated with glucocorticoids. Similarly, patients with clinically significant lung disease requiring O2 support or impaired lung function per investigator should be excluded

7. History of allergic reactions attributed to compound of similar chemical or biologic composition to the agent(s) used in this study

8. Patients receiving any medications or substances that are strong inhibitors or inducers of Neratinib and/or TDxD are ineligible.

9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

10. Has a QT interval corrected by Fridericia's formula (QTcF) prolongation to >470 msec (female subjects) or >450 msec (male subjects) based on average of the Screening triplicate12-lead ECG.

11. Any patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, including uncontrolled HIV with CD4 count <200, untreated Hepatitis B are excluded from the study. Patients who have been treated for hepatitis C definitively with evidence of sustained virologic response, as well as HIV and hepatitis B patients on treatment with undetectable viral load will be eligible for inclusion.

12. Pregnant or breast feeding.

Related Conditions & MeSH terms

• Esophageal Neoplasms
• Gastric Cancer

Intervention

Drug:
• Neratinib Pill
Patients will be enrolled in cohorts of 3 at each dose level of Neratinib (120 mg, 160 mg, 200 mg) daily (days 1 through 21)
• Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
standard dosing of TDxD (5.4mg/m2) on day 1of a 21 day treatment cycle

Locations

Country	Name	City	State
United States	Roswell Park Comprehensive Cancer Center	Buffalo	New York
United States	Stanford Cancer Center	Palo Alto	California
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania

Sponsors (3)

Lead Sponsor	Collaborator
Fox Chase Cancer Center	National Comprehensive Cancer Network, Puma Biotechnology, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of the combination of TDxD and Neratinib	Determine the MTD and RP2D by assessing the rate of dose-limiting toxicities (DLTs) for the combination of Neratinib + TDxD during DLT period of 28 days, in patients with advanced gastroesophageal cancer.	2 years
Secondary	Determine the Objective Response Rate (ORR) (Complete Response (CR) + Partial Response (PR)) of the combination of TDxD and Neratinib	Determine the rate of grade 3 or higher adverse events with Neratinib combination with TDxD in patients with advanced gastroesophageal cancer.	2 years
Secondary	Determine the Disease Control Rate (DCR) (CR + PR + Stable Disease (SD)) of the combination of TDxD and Neratinib	Disease Control Rate (DCR) of the combination of TDxD and Neratinib in patients with advanced gastroesophageal cancer (Complete and partial response per RECIST 1.1)	2 years
Secondary	Determine the Progression Free Survival (PFS) of the combination of TDxD and Neratinib	Progression Free Survival (PFS) of the combination of TDxD and Neratinib in patients with advanced gastroesophageal cancer (time from treatment initiation to disease progression or death from any cause).	2 years
Secondary	Determine the Overall Survival (OS) of the combination of TDxD and Neratinib	Overall Survival (OS) of the combination of TDxD and Neratinib in patients with advanced gastroesophageal cancer (defined as the time from treatment initiation to death from any cause)	2 years